{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MESNA", "query": { "intervention": "MESNA" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 272, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MESNA&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T09:22:59.993Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05566223", "title": "CISH Inactivated TILs in the Treatment of NSCLC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Metastatic Non Small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Adenocarcinoma of Lung", "Large Cell Lung Cancer" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CISH Inactivated TIL", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intima Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2023-02", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 2, "location_summary": "Duarte, California • Minneapolis, Minnesota", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05566223" }, { "nct_id": "NCT06001385", "title": "HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Leukemia", "Myelodysplastic Syndromes", "Chronic Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Myeloproliferative Neoplasm", "Lymphoma", "Chronic Myelomonocytic Leukemia", "Pro-Lymphocytic Leukemia", "Myelofibrosis" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "PBSC Hematopoietic Stem Cell Transplantation (HSCT)", "type": "PROCEDURE" }, { "name": "Post-Transplant Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Patient Reported Outcomes", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total-body irradiation", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 313, "start_date": "2023-12-08", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 32, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06001385" }, { "nct_id": "NCT03829566", "title": "Autologous Transplant To End NMO Spectrum Disorder", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Neuromyelitis Optica", "Devic's Disease", "NMO Spectrum Disorder" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "rATG", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Autologous Stem Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2025-11-28", "has_results": false, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 2, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829566" }, { "nct_id": "NCT04047628", "title": "Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis", "Relapsing Remitting Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Best Available Therapy (BAT)", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 156, "start_date": "2019-12-19", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 22, "location_summary": "Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04047628" }, { "nct_id": "NCT02164097", "title": "ODSH + ICE Chemotherapy in Pediatric Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Solid Tumor", "Refractory Solid Tumor", "Sarcoma", "Wilms' Tumor", "Neuroblastoma" ], "interventions": [ { "name": "ODSH", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 4, "start_date": "2015-01", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164097" }, { "nct_id": "NCT03577431", "title": "Liver Transplantation With Tregs at MGH", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "arTreg-CSB", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 9, "start_date": "2019-03-29", "completion_date": "2027-04-06", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03577431" }, { "nct_id": "NCT05579769", "title": "Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancy", "Myeloid Malignancy" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Anti-thymocyte globulin (ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Total Body Irradiation (radiation treatment)", "type": "RADIATION" }, { "name": "Bone marrow infusion", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 3, "start_date": "2023-03-14", "completion_date": "2024-05-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579769" }, { "nct_id": "NCT00067002", "title": "Randomized Double Cord Blood Transplant Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Acute", "Leukemia, Myelocytic, Acute", "Leukemia, Myeloid, Chronic", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Expanded allogeneic cord blood (CB)", "type": "PROCEDURE" }, { "name": "One Unmanipulated and One Expanded Cord Blood Unit", "type": "PROCEDURE" }, { "name": "Rituxan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Total body irradiation (TBI)", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "80 Years", "sex": "ALL", "summary": "1 Month to 80 Years" }, "enrollment_count": 110, "start_date": "2003-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2019-05-01", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00067002" }, { "nct_id": "NCT03654040", "title": "Liver Transplantation With Tregs at UCSF", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "arTreg", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 42, "start_date": "2021-04-22", "completion_date": "2023-03-06", "has_results": true, "last_update_posted_date": "2024-04-23", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654040" }, { "nct_id": "NCT01096368", "title": "Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaplastic Ependymoma", "Brain Ependymoma", "Cellular Ependymoma", "Clear Cell Ependymoma", "Ependymoma", "Papillary Ependymoma" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Clinical Observation", "type": "OTHER" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 479, "start_date": "2010-05-07", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-09-02T09:22:59.993Z", "location_count": 181, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01096368" } ] }